Dyax Corp Receivables Turnover Ratio (DYAX), from the third quarter 2015 to the third quarter 2014 current and historic results, rankings and more - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Sales per Employee
• Income per Employee
• Inventory Turnover
• Asset Turnover
• Receivables Turnover
Dyax Corp  (DYAX)
    Sector • Healthcare    Industry • Medical Laboratories
   Industry • Medical Laboratories
   Sector • Healthcare
 

Dyax Accounts Receivables Turnover Ratio from the third quarter 2015 to the third quarter 2014

Quarterly Results, Trends, Rankings, Statistics


Dyax Corp's ability to collect accounts receivable sequentially worsen to 8.49, pointing to a challenging and on top of that deteriorating business climate for the Medical Laboratories industry. Dyax's Accounts Receivable average collection period in the Sep 30 2015 quarter, has increased to 43 days, from 37 days, in the Jun 30 2015 quarter.

If we take a look into Healthcare sector 131 other companies have achieved higher receivables turnover ratio. While receivables turnover ratio total ranking has improved thus far to 1761, from overall ranking in the second quarter 2015 at 2786.

What is Receivable Turnover Ratio?
What is Dyax Corp Selling?


What is Receivable Turnover Ratio?




Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

DYAX Receivables Turnover Ratio (Sep 30 2015)
III. Quarter		 (Jun 30 2015)
II. Quarter		 (Mar 31 2015)
I. Quarter		 (Dec 31 2014)
IV. Quarter		 (Sep 30 2014)
III. Quarter
Y / Y Receivable Change 116.17 % 108.62 % 90.05 % 87.84 % -1.91 %
Y / Y Revenue Change 12.44 % 34.66 % 44.63 % 54.39 % 60.64 %
Receivable Turnover Ratio (TTM) 8.49 9.75 10.6 11.42 12.66
DYAX's Total Ranking # 1761 # 2786 # 1730 # 2786 # 2786
Accounts Receivable average collection period days 43 37 34 32 29
Seq. Receivable Change 20.48 % 13.41 % -21.08 % 100.48 % 16.27 %
Seq. Revenue Change -6.23 % 29.17 % -21.55 % 18.35 % 12.3 %


Receivable Turnover Company Ranking
Within: No.
Medical Laboratories Industry # 9
Healthcare Sector # 132
Overall Market # 1761

Receivable Turnover Ratio Statistics
High Average Low
12.48 9.78 8.24
(Sep 30 2014)   (Sep 30 2013)





DYAX Company Profile • Back to DYAX Efficiency Comparisons • Compare DYAX Receivables Turnover Ratio to its Competitors

Financial Statements
Dyax's Accounts Receivable $ 13 Millions Visit DYAX's Balance sheet
Dyax's Sales TTM $ 98 Millions Visit DYAX's Income Statement
Sources of DYAX's Revenues Visit DYAX's Sales by Geography

Other Accounts Receivable Turnover Ratios
Medical Laboratories Industry Accounts Receivable Turnover Trends and Statistics
Healthcare Sector Accounts Receivable Turnover Statistics
Accounts Receivables Turnover Trends for overall market
DYAX's Receivable Turnover Ratio versus Medical Laboratories Industry, Healthcare Sector and total Market
Highest Ranking Accounts Receivables Turnover
Lowest Ranking Accounts Receivables Turnover

You may also want to know
DYAX's Growth Rates DYAX's Roa DYAX's Inventory Turnover Ratio DYAX's Dividend Comparisons
DYAX's Profitability Ratios DYAX's Roi DYAX's Asset Turnover Ratio DYAX's Dividend Growth
DYAX's Valuation Ratios DYAX's Roe DYAX's Financial Strength Ratios DYAX's Dividend Payout Ratio



Companies with similar Receivables Turnover Ratio for the quarter ending Sep 30 2015, within Healthcare Sector Receivable Turnover Ratio Revenues for 12 Months ending Sep 30 2015 Receivable at quarter ending Sep 30 2015
Cti Biopharma Corp   19.70 $ 22.581  Millions$ 1.146  Millions
Biocept Inc   18.95 $ 0.467  Millions$ 0.025  Millions
Immunogen inc   18.86 $ 87.189  Millions$ 4.623  Millions
First Choice Healthcare Solutions Inc   18.04 $ 44.006  Millions$ 2.440  Millions
Rigel Pharmaceuticals Inc  17.97 $ 28.608  Millions$ 1.592  Millions
Pacific Biosciences Of California Inc   17.47 $ 73.405  Millions$ 4.202  Millions
Cyclo Therapeutics Inc   17.39 $ 1.234  Millions$ 0.071  Millions
Vystar Corporation  16.57 $ 0.470  Millions$ 0.028  Millions
Alaunos Therapeutics Inc   16.56 $ 2.753  Millions$ 0.166  Millions
Ethema Health Corporation   16.35 $ 1.916  Millions$ 0.117  Millions
International Stem Cell Corporation  15.85 $ 7.390  Millions$ 0.466  Millions
Pacira Biosciences inc   15.55 $ 377.345  Millions$ 24.269  Millions
United Cannabis Corp  15.54 $ 0.631  Millions$ 0.041  Millions
Acorda Therapeutics Inc   15.43 $ 479.629  Millions$ 31.079  Millions
Harrow Inc   15.05 $ 6.763  Millions$ 0.449  Millions
Veracyte Inc   14.99 $ 47.660  Millions$ 3.180  Millions
Biocorrx Inc   14.80 $ 1.220  Millions$ 0.082  Millions
Epizyme Inc.  14.80 $ 12.354  Millions$ 0.835  Millions
Oncomed Pharmaceuticals Inc  14.78 $ 27.575  Millions$ 1.866  Millions
Miragen Therapeutics Inc   14.59 $ 3.625  Millions$ 0.249  Millions
Semler Scientific inc   14.51 $ 5.122  Millions$ 0.353  Millions
Apyx Medical Corp  14.42 $ 28.691  Millions$ 1.989  Millions
Wearable Health Solutions, Inc.  14.19 $ 1.205  Millions$ 0.085  Millions
Sanuwave Health Inc   14.17 $ 0.831  Millions$ 0.059  Millions
Sunlink Health Systems Inc   14.15 $ 76.738  Millions$ 5.423  Millions
Nanomix Corp  14.01 $ 0.108  Millions$ 0.008  Millions
Caredx Inc   13.98 $ 29.448  Millions$ 2.107  Millions
Bioxytran Inc   13.70 $ 0.221  Millions$ 0.016  Millions
Scynexis Inc   13.66 $ 8.722  Millions$ 0.639  Millions
Integrated Biopharma Inc  13.21 $ 38.351  Millions$ 2.903  Millions

Date modified: 2026-08-29T13:43:07+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.